N-of-1 trial for Andersen-Tawil syndrome and MEPPC
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests personalized medication strategies for people with Andersen-Tawil syndrome (ATS) or a specific type of heart condition called MEPPC. It aims to find the safest and most effective treatment for managing heart rhythm issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Andersen-Tawil syndrome (ATS) or MEPPC with a confirmed genetic change.
- You have had a history of abnormal heart rhythms (ventricular arrhythmia) seen on heart monitoring.
- You are currently taking the heart medication flecainide.
- You are 18 years or older.
- You are not pregnant, do not have other serious heart disease, and can take oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
This trial tests whether the medication flecainide can reduce frequent extra heartbeats (called PVCs) that come from normal heart tissue, and may help prevent or reverse heart muscle problems caused by these extra beats.
This trial uses a home heart monitor (a chest patch with an ECG) to study how atrial fibrillation (an irregular heartbeat) changes over time and how this may help manage symptoms. You may be included if you have a documented, short-lasting type of atrial fibrillation and a moderate amount of AF seen on a 14-day heart recording.
This trial studies whether a device-based fast pacing therapy (called ATP) can better treat certain rapid heart rhythm problems in people born with a heart condition. It may help prevent or reduce episodes of atrial (upper-chamber) arrhythmias that occur despite having a pacing/defibrillator device.
This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.
This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.
Hear when a new Andersen Tawil Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.